Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Andrew Scott following the successful completion of the phase I trial for its ultra-rapid acting insulin for diabetics.
She says the product was shown to have a favourable profile when compared with standard treatments and the complete results have been submitted for publication at a big diabetes conference next year.